Novel drugs for older patients with acute myeloid leukemia, Leukemia, vol.29, pp.760-769, 2015. ,
An update of current treatments for adult acute myeloid leukemia, Blood, vol.127, pp.53-61, 2016. ,
Acute myeloid leukemia, N Engl J Med, vol.373, pp.1136-52, 2015. ,
Hallmarks of cancer: The next generation, Cell, vol.144, pp.646-74, 2011. ,
Altered metabolite levels in cancer: implications for tumour biology and cancer therapy, Nat Rev Cancer, vol.16, pp.680-93, 2016. ,
The emerging hallmarks of cancer metabolism, Cell Metab, vol.23, pp.27-47, 2016. ,
The metabolism of tumors in the body, J Gen Physiol, vol.8, pp.519-549, 1927. ,
On the origin of cancer cells, Science, vol.123, pp.309-323, 1956. ,
The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome, J Leukoc Biol, vol.89, pp.51-56, 2011. ,
A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value, Blood, vol.124, pp.1645-54, 2014. ,
Cellstate-specific metabolic dependency in hematopoiesis and leukemogenesis, Cell, vol.158, pp.1309-1332, 2014. ,
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells, Leukemia, vol.31, pp.2326-2361, 2017. ,
Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming, Oncotarget, vol.8, pp.67639-50, 2017. ,
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling, Nat Cell Biol, vol.17, pp.1484-96, 2015. ,
Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin, Oncogene, vol.36, pp.254-62, 2017. ,
Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin, Leuk Res, vol.35, pp.814-834, 2011. ,
Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia, Expert Opin Ther Targets, vol.21, pp.705-719, 2017. ,
Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia, Cancer Biol Ther, vol.16, pp.648-56, 2015. ,
Antileukemic activity of rapamycin in acute myeloid leukemia, Blood, vol.105, pp.2527-2561, 2005. ,
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia, Leukemia, vol.26, pp.1195-202, 2012. ,
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia, Blood, vol.114, pp.1618-1645, 2009. ,
Autophagy is essential to suppress cell stress and to allow BCR-Ablmediated leukemogenesis, Oncogene, vol.30, pp.1855-67, 2011. ,
Antileukemic activity of 2-deoxy-D-glucose through inhibition of N-linked glycosylation in acute myeloid leukemia with FLT3-ITD or c-KIT mutations, Mol Cancer Ther, vol.14, pp.2364-73, 2015. ,
ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition, Leukemia, vol.31, pp.2143-50, 2017. ,
Abstract B126: AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies, Therapeutic agents: Other topics, pp.126-132, 2018. ,
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression, Leuk Res, vol.27, issue.02, pp.85-86, 2003. ,
Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines, J Investig Med, vol.49, pp.319-343, 2001. ,
Interaction of cytosine arabinoside and lovastatin in human leukemia cells, Leuk Res, vol.25, issue.00, pp.162-166, 2001. ,
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study, Blood, vol.109, pp.2999-3006, 2007. ,
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML), Leuk Res, vol.67, pp.17-20, 2018. ,
Drug redeployment to kill leukemia and lymphoma cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids, Cancer Res, vol.75, pp.2530-2570, 2015. ,
Combined bezafibrate and medroxyprogesterone acetate: Potential novel therapy for acute myeloid leukaemia, PLoS One, vol.4, 2009. ,
Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML), Br J Haematol, vol.149, pp.65-74, 2010. ,
Biological aspects of mTOR in leukemia, Int J Mol Sci, vol.19, p.2396, 2018. ,
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia, Blood, vol.122, pp.3521-3553, 2013. ,
Regulation of TORC1 by Rag GTPases in nutrient response, Nat Cell Biol, vol.10, pp.935-980, 2008. ,
Bidirectional transport of amino acids regulates mTOR and autophagy, Cell, vol.136, pp.521-555, 2009. ,
Glutamine and cancer: cell biology, physiology, and clinical opportunities, J Clin Invest, vol.123, pp.3678-84, 2013. ,
From Krebs to clinic: glutamine metabolism to cancer therapy, Nat Rev Cancer, vol.16, pp.619-653, 2016. ,
Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis, Proc Natl Acad Sci U S A, vol.104, pp.19345-50, 2007. ,
Understanding the intersections between metabolism and cancer biology, Cell, vol.168, pp.657-69, 2017. ,
Metabolic pathways promoting cancer cell survival and growth, Nat Cell Biol, vol.17, pp.351-360, 2015. ,
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis, Nature, vol.527, pp.379-83, 2015. ,
Vander Heiden MG. Targeting metabolism for cancer therapy, Cell Chem Biol, vol.24, pp.1161-80, 2017. ,
Cellular fatty acid metabolism and cancer, Cell Metab, vol.18, pp.153-61, 2013. ,
Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells, Cancer Res, vol.56, pp.745-51, 1996. ,
Malonate as a ROS product is associated with pyruvate carboxylase activity in acute myeloid leukaemia cells, Cancer Metab, vol.4, p.15, 2016. ,
Nonezymatic formation of succinate in mitochondria under oxidative stress, Free Radic Biol Med, vol.41, pp.56-64, 2006. ,
Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines, PLoS One, vol.4, p.4251, 2009. ,
Reversible activation of the mammalian enzyme, J Biol Chem, vol.13, pp.4987-93, 1967. ,
Inhibition by malonate of succinic dehydrogenase in heartmuscle preparations, Biochem J, vol.54, pp.540-547, 1953. ,
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS, Nature, vol.515, pp.431-436, 2014. ,
Pyruvate carboxylase is up-regulated in breast cancer and essential to support growth and invasion of MDA-MB-231 cells, PLoS One, vol.10, 2015. ,
Mass spectrometry analysis shows the biosynthetic pathways supported by pyruvate carboxylase in highly invasive breast cancer cells, Biochim Biophys Acta Mol Basis Dis, vol.1863, pp.537-51, 2017. ,
Pyruvate carboxylase is required for glutamine-independent growth of tumor cells, Proc Natl Acad Sci U S A, vol.108, pp.8674-8683, 2011. ,
Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation, J Clin Invest, vol.125, pp.687-98, 2015. ,
Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer, Cell Metab, vol.23, pp.517-545, 2016. ,
Breast cancer-derived lung metastases show increased pyruvate carboxylase-dependent anaplerosis, Cell Rep, vol.17, pp.837-885, 2016. ,
Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice, Br J Haematol, vol.102, pp.522-529, 1998. ,
Cholesterol biosynthesis: A mechanistic overview, Biochemistry, vol.55, pp.5483-506, 2016. ,
Otto Warburg's contributions to current concepts of cancer metabolism, Nat Rev Cancer, vol.11, pp.325-362, 2011. ,
On respiratory impairment in cancer cells, Science, vol.124, pp.267-276, 1956. ,
Studies on the fate of isotopically labeled metabolites in the oxidative metabolism of tumors, Cancer Res, vol.11, pp.585-91, 1951. ,
Oxidative metabolism of neoplastic tissues, Adv Cancer Res, vol.3, pp.60922-60929, 1955. ,
AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress, Blood, vol.125, pp.2120-2150, 2015. ,
Amplification of mitochondrial DNA in acute myeloid leukaemia, Br J Haematol, vol.95, pp.426-457, 1996. ,
A mitochondrial drug to treat AML, Blood, vol.129, pp.2597-2606, 2017. ,
Indirect inhibition of mitochondrial dihydroorotate dehydrogenase activity by nitric oxide, Free Radic Biol Med, vol.28, issue.00, pp.239-241, 2000. ,
Cancer metabolism: fatty acid oxidation in the limelight, Nat Rev Cancer, vol.13, pp.227-259, 2013. ,
High expression of CPT1A predicts adverse outcomes: A potential therapeutic target for acute myeloid leukemia, EBioMedicine, vol.14, pp.55-64, 2016. ,
Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism, Cancer Discov, vol.7, pp.716-751, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01608532
PHD3 Loss in cancer enables metabolic reliance on fatty acid oxidation via deactivation of ACC2, Mol Cell, vol.63, pp.1006-1026, 2016. ,
Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK, Biochem Biophys Res Commun, vol.391, pp.187-92, 2010. ,
Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase, Biochem Soc Trans, vol.30, pp.1064-70, 2002. ,
Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells, Leukemia, vol.29, pp.1555-63, 2015. ,
Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential, Cancer Cell, vol.30, pp.779-91, 2016. ,
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes, Oncotarget, vol.7, pp.79722-79757, 2016. ,
Gls inhibitor CB-839 modulates cellular metabolism in AML and potently suppresses AML cell growth when combined with 5-azacitidine, Blood, vol.128, p.4064, 2016. ,
Exploiting AML vulnerability: glutamine dependency, Blood, vol.126, pp.1269-70, 2015. ,
Methylation analysis of asparagine synthetase gene in acute lymphoblastic leukemia cells, Leukemia, vol.20, pp.1303-1309, 2006. ,
Acute myeloid leukaemia niche regulates response to L-asparaginase, Br J Haematol, 2019. ,
Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine, Cancer Res, vol.73, pp.2998-3006, 2013. ,
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach, Blood, vol.93, pp.1308-1326, 1999. ,
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome, Am J Hematol, vol.90, pp.483-489, 2015. ,
GAPDH expression predicts the response to R-CHOP, the tumor metabolic status, and the response of DLBCL patients to metabolic inhibitors, Cell Metab, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02359440
Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells, Apoptosis, vol.20, pp.1099-108, 2015. ,
Phase I and pharmacokinetic study of brequinar sodium, vol.368390 ,
, Cancer Res, vol.50, pp.4595-4604, 1990.
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies, Invest New Drugs, vol.16, pp.19-27, 1998. ,
Phase I clinical and pharmacokinetic trial of Brequinar sodium ,
, NSC 368390), vol.49, pp.4648-53, 1989.
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies, Cancer Chemother Pharmacol, vol.25, pp.345-51, 1990. ,
Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor, Nucleosides Nucleotides Nucleic Acids, vol.37, pp.1-13, 2018. ,
Diagnosing and exploiting cancer's addiction to blocks in apoptosis, Nat Rev Cancer, vol.8, pp.121-153, 2008. ,
tBid induces alterations of mitochondrial fatty acid oxidation flux by malonyl-CoA-independent inhibition of carnitine palmitoyltransferase-1, Cell Death Differ, vol.12, pp.603-616, 2005. ,
Direct interaction of the mitochondrial membrane protein carnitine palmitoyltransferase I with Bcl-2, Biochem Biophys Res Commun, vol.231, pp.523-528, 1997. ,
Statins enhance efficacy of venetoclax in blood cancers, Sci Transl Med, vol.10, p.1240, 2018. ,
Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity, Cell Metab, 2019. ,
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, vol.129, pp.424-471, 2017. ,
Recurring mutations found by sequencing an acute myeloid leukemia genome, N Engl J Med, vol.361, pp.1058-66, 2009. ,
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value, Blood, vol.116, pp.2122-2128, 2010. ,
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study, J Clin Oncol, vol.28, pp.2348-55, 2010. ,
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication, J Clin Oncol, vol.28, pp.3636-3679, 2010. ,
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature, vol.462, pp.739-783, 2009. ,
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate, Cancer Cell, vol.17, pp.225-259, 2010. ,
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation, Cancer Cell, vol.18, pp.553-67, 2010. ,
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence, Nat Genet, vol.50, pp.62-72, 2018. ,
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function, Genes Dev, vol.26, pp.2038-2087, 2012. ,
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation, Science, vol.340, pp.622-628, 2013. ,
Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas, JNCI J Natl Cancer Inst, vol.104, pp.1458-69, 2012. ,
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2, Nat Commun, vol.4, p.2166, 2013. ,
Insulator dysfunction and oncogene activation in IDH mutant gliomas, Nature, vol.529, pp.110-114, 2016. ,
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1, Proc Natl Acad Sci U S A, vol.114, pp.10743-10751, 2017. ,
IDH1 Mutation promotes tumorigenesis by inhibiting JNK activation and apoptosis induced by serum starvation, Cell Rep, vol.19, pp.389-400, 2017. ,
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia, J Exp Med, vol.213, pp.483-97, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01886383
Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance, Cell Stem Cell, vol.14, pp.329-370, 2014. ,
R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible, Science, vol.339, pp.1621-1626, 2013. ,
Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis, Leukemia, vol.28, pp.2276-82, 2014. ,
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia, Nature, vol.506, pp.328-361, 2014. ,
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia, Nat Chem Biol, vol.11, pp.878-86, 2015. ,
Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo, ACS Med Chem Lett, vol.3, pp.850-855, 2012. ,
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells, Science, vol.340, pp.626-656, 2013. ,
Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant hematologic malignancies ,
, Haematologica, vol.100, pp.214-219, 2015.
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations, Nature, vol.559, pp.125-134, 2018. ,
Optimizing next-generation AML therapy: Activity of mutant IDH2 inhibitor AG-221 in preclinical models, Cancer Discov, vol.7, pp.459-61, 2017. ,
Biological role and therapeutic potential of IDH mutations in cancer, Cancer Cell, 2018. ,
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism, Cancer Res, vol.74, pp.3317-3348, 2014. ,
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1, Cancer Res, vol.70, pp.8981-8988, 2010. ,
Transaminase inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma, Cell, vol.175, pp.101-117, 2018. ,
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1, Nat Med, vol.19, pp.901-909, 2013. ,
BCAT1 restricts ?KG levels in AML stem cells leading to IDHmut-like DNA hypermethylation, Nature, vol.551, pp.384-392, 2017. ,
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype, Oncotarget, vol.6, pp.12279-96, 2015. ,
Integrative genomic analysis of cholangiocarcinoma identifies distinct IDHmutant molecular profiles, Cell Rep, vol.19, pp.2878-80, 2017. ,
In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma, Oncotarget, vol.8, pp.49165-77, 2017. ,
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha, Science, vol.324, pp.261-266, 2009. ,
The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma, Acta Neuropathol, vol.119, pp.487-94, 2010. ,
Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198, Cancer Res, vol.75, pp.4790-802, 2015. ,
Consumption of NADPH for 2-HG synthesis increases pentose phosphate pathway flux and sensitizes cells to oxidative stress, Cell Rep, vol.22, pp.512-534, 2018. ,
Oncogenic IDH1 mutations promote enhanced proline synthesis through PYCR1 to support the maintenance of mitochondrial redox homeostasis, Cell Rep, vol.22, pp.3107-3121, 2018. ,
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia, Nat Med, vol.21, pp.178-84, 2015. ,
Acute myeloid leukemia: 2019 update on risk-stratification and management, Am J Hematol, vol.93, pp.1267-91, 2018. ,
Classification and risk assessment in AML: integrating cytogenetics and molecular profiling, Hematol Am Soc Hematol Educ Progr, vol.2017, pp.37-44, 2017. ,
Genomic classification and prognosis in acute myeloid leukemia, N Engl J Med, vol.374, pp.2209-2230, 2016. ,
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N Engl J Med, vol.368, pp.2059-74, 2013. ,
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status, J Clin Oncol, vol.31, pp.3681-3688, 2013. ,
Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/ refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transpplantation, Blood, vol.120, 2012. ,
Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?, Curr Opin Hematol, vol.21, pp.72-80, 2014. ,
ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia, Proc Natl Acad Sci U S A, vol.113, pp.6669-78, 2016. ,
ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair, EMBO J, vol.30, pp.546-55, 2011. ,
Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia, Exp Hematol, vol.58, pp.52-60, 2018. ,
Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations, Clin Cancer Res, vol.21, pp.1360-72, 2015. ,
Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition, Blood, vol.131, pp.1639-53, 2018. ,
Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells, Cell Rep, vol.7, pp.1248-58, 2014. ,
glycine and one-carbon units: cancer metabolism in full circle, Nat Rev Cancer, vol.13, pp.572-83, 2013. ,
One-carbon metabolism in cancer, Br J Cancer, vol.116, pp.1499-504, 2017. ,
Serine and one-carbon metabolism in cancer, Nat Rev Cancer, vol.16, pp.650-62, 2016. ,
One-carbon metabolism in health and disease, Cell Metab, vol.25, pp.27-42, 2017. ,
Vander Heiden MG. The importance of serine metabolism in cancer, J Cell Biol, vol.214, pp.249-57, 2016. ,
Modulating the therapeutic response of tumours to dietary serine and glycine starvation, Nature, vol.544, pp.372-378, 2017. ,
Serine and glycine metabolism in cancer, Trends Biochem Sci, vol.39, pp.191-199, 2014. ,
Targeting MTHFD2 in acute myeloid leukemia, J Exp Med, vol.213, pp.1285-306, 2016. ,
Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2-and TET2-mutant acute myeloid leukemia, Cancer Discov, vol.7, pp.494-505, 2017. ,
Mutant and wild-type isocitrate dehydrogenase 1 share enhancing mechanisms involving distinct tyrosine kinase cascades in cancer. Cancer Discov, 2019. ,
Rigorous replication effort succeeds for just two of five cancer papers ,
Raise standards for preclinical cancer research, Nature, vol.483, pp.531-534, 2012. ,
Cancer reproducibility project releases first results, Nature, vol.541, pp.269-70, 2017. ,
Metabolic heterogeneity in human lung tumors, Cell, vol.164, pp.681-94, 2016. ,
Vander Heiden MG. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition, Elife, vol.6, 2017. ,
High drug attrition rates-where are we going wrong?, Nat Rev Clin Oncol, vol.8, pp.189-90, 2011. ,
Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase, Cell, vol.169, pp.258-272, 2017. ,
Improving the metabolic fidelity of cancer models with a physiological cell culture medium, Sci Adv, vol.5, 2019. ,
Inferring cancer dependencies on metabolic genes from large-scale genetic screens, BMC Biol, vol.17, p.37, 2019. ,
Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine, Sci Rep, vol.8, p.16837, 2018. ,
Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells, Cancer Cell, vol.34, pp.659-673, 2018. ,
The nutrient environment affects therapy, Science, vol.360, pp.962-965, 2018. ,
Diet boosts the effectiveness of a cancer drug, Nature, vol.560, pp.439-479, 2018. ,
Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion, Nature, vol.536, pp.479-83, 2016. ,
Microenvironmental autophagy promotes tumour growth, Nature, vol.541, pp.417-437, 2017. ,
Autophagy maintains tumour growth through circulating arginine, Nature, vol.563, pp.569-73, 2018. ,
Evolution of acute myelogenous leukemia stem cell properties after treatment and progression, Blood, vol.128, pp.1671-1679, 2016. ,
Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence, Cancer Cell, vol.34, pp.483-498, 2018. ,
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies, Am J Hematol, vol.93, pp.401-408, 2018. ,
Metabolic flexibility in leukemia-adapt or die, Cancer Cell, vol.34, pp.695-701, 2018. ,
Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo, Cell Metab, vol.28, pp.793-800, 2018. ,
Lactate metabolism in human lung tumors, Cell, vol.171, pp.358-371, 2017. ,
, Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations